Media stories about Pieris Pharmaceuticals (NASDAQ:PIRS) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pieris Pharmaceuticals earned a daily sentiment score of 0.02 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.4956079986013 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Why is the 20 Simple Moving Average (SMA) so common for traders and analysts? Pieris Pharmaceuticals, Inc … (thestreetpoint.com)
- Really worthy Stock of Wednesday— Pieris Pharmaceuticals, Inc. (PIRS) (stockmarketstop.com)
- Reeling Three Stocks: McEwen Mining Inc. (NYSE:MUX), Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), PH Glatfelter … (thestreetpoint.com)
- Active Stock’s Momentum: Seadrill Limited (NYSE:SDRL), Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), Xtant Medical … (stocksnewspoint.com)
- Stocks Alert: Hovnanian Enterprises, Inc. (NYSE:HOV), Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), Rafael Holdings … (stocksnewspoint.com)
A number of analysts recently weighed in on PIRS shares. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Pieris Pharmaceuticals in a report on Friday, March 9th. Jefferies Financial Group started coverage on Pieris Pharmaceuticals in a report on Monday, March 19th. They issued a “buy” rating and a $12.00 price objective for the company. Cowen started coverage on Pieris Pharmaceuticals in a report on Friday, May 4th. They issued an “outperform” rating for the company. ValuEngine upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Evercore ISI started coverage on Pieris Pharmaceuticals in a report on Monday, March 19th. They issued an “outperform” rating and a $13.00 price objective for the company. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Pieris Pharmaceuticals currently has an average rating of “Buy” and an average price target of $12.33.
Pieris Pharmaceuticals traded down $0.33, reaching $5.32, during trading hours on Thursday, MarketBeat Ratings reports. 1,000,600 shares of the company’s stock were exchanged, compared to its average volume of 732,855. Pieris Pharmaceuticals has a twelve month low of $4.11 and a twelve month high of $9.75. The company has a market cap of $314.67 million, a P/E ratio of -13.30 and a beta of 1.65.
Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.14). Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%. The business had revenue of $4.15 million for the quarter, compared to analyst estimates of $11.39 million. analysts forecast that Pieris Pharmaceuticals will post -0.48 earnings per share for the current fiscal year.
In related news, Director James A. Geraghty acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were bought at an average price of $5.75 per share, with a total value of $57,500.00. Following the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at $115,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Orbimed Advisors Llc sold 1,000,000 shares of the firm’s stock in a transaction dated Monday, April 30th. The shares were sold at an average price of $6.35, for a total transaction of $6,350,000.00. The disclosure for this sale can be found here. 4.05% of the stock is owned by corporate insiders.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.